#STATISTICAL CALCULATIONS FOR TRIALS FULL#

The trial was sponsored by the charity St George Street Capital. The trial was conducted at 28 hospitals in the UK, Romania and the Czech Republic. The ARCADIA Trial was a double-blind, randomised, placebo-controlled, clinical trial to evaluate AZD1656 in the treatment of diabetic patients hospitalised with COVID-19. Immunophenotyping data suggested that AZD1656-treated patients had a less pro-inflammatory immune response and a better adaptive immune response than those treated with placebo. A difference between groups in time to hospital discharge was also seen ( p=0♱6).

At Day 7 there were zero deaths in the AZD1656 group compared to six deaths in the placebo group ( p=0♰11, post hoc). Mortality was lower in the AZD1656 group compared to the placebo group (AZD1656: four (5%) Placebo: nine (12♳%), p=0♰90)). There was no difference in the number of adverse events between groups (AZD1656: 35♷% Placebo: 33♳%). The primary analysis showed no statistically significant difference between groups (AZD1656: 76♳% Placebo: 69♹%, p=0♱9).

#STATISTICAL CALCULATIONS FOR TRIALS FULL#

Of the remaining 153, 80 were assigned to AZD1656 and 73 were assigned to placebo and included in the Full Analysis Set (FAS). The Lancet Regional Health – Western Pacificīetween 29 September 2020 to 16 April 2021, 170 patients were screened and 156 patients were randomised, three of whom did not commence treatment.

The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology.

Statistical calculations for trials